4D Molecular Therapeutics FDMT Prepaid & Other Current
Prepaid & Other Current at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's prepaid & other current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's prepaid & other current?
- 4D Molecular Therapeutics (FDMT) reported prepaid & other current of $14.47M in Q1 2026.
- How has 4D Molecular Therapeutics's prepaid & other current changed year-over-year?
- 4D Molecular Therapeutics's prepaid & other current increased by 30.0% year-over-year, from $11.13M to $14.47M.
- What is the long-term trend for 4D Molecular Therapeutics's prepaid & other current?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's prepaid & other current has grown at a 19.4% compound annual growth rate (CAGR), from $19.19M to $38.98M.
- What does prepaid & other current mean?
- Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.